The global microbiome sequencing services market was valued at USD 286 million in 2023 and is expected to grow at a CAGR of 15.30% during the forecast period.Metagenomics sequencing has become an essential tool for studying the gut microbiome, as it allows researchers to identify and analyze the genetic material of all the microorganisms present in a sample. This technology has led to significant advancements in gut research, providing insights into the composition and function of the gut microbiome, and how it interacts with the host organism. Furthermore, the demand for NGS has increased as it provides faster and more accurate sequencing results compared to traditional sequencing methods, which has contributed to the growth of the market.
To Understand More About this Research: Request A Free Sample Report
The microbiome sequencing technology has opened new avenues for diagnosing and treating a wide range of diseases, including infectious diseases, metabolic disorders, autoimmune disorders, and even certain types of cancer. The use of NGS and bioinformatics algorithms has enabled researchers to identify and characterize the microorganisms that make up the microbiome, which in turn has led to a better understanding of their functions and interactions with the human body. This knowledge has potential applications in developing targeted therapies that could improve health outcomes for patients.
The development of advanced tools and software for microbiome sequencing analysis is expected to contribute to the growth of the market in the forecast years. The software tool developed by Texas Biomedical Research Institute and Tulane University can help drug developers and microbiologists to study diseases like cancer, COVID-19, HIV/AIDS, malaria, and other medical conditions related to microorganisms. This is just one example of the numerous innovations that are being developed to improve microbiome sequencing analysis and research, which is expected to drive market growth in the coming years.
The COVID-19 pandemic led to an increased focus on studying the microbiome and its role in infectious diseases, including COVID-19. This, in turn, increased the demand for microbiome sequencing services. However, as the pandemic situation is improving, the market is expected to continue growing due to the increasing application of microbiome sequencing in areas such as personalized medicine, agriculture, and environmental studies.
Growth Drivers
The creation of a low-cost metagenome sequencing technology by the Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) is a significant contribution to the microbiome sequencing market. This technology can be particularly useful in studying microbiomes that have low levels of biomass, damage, or contamination. It can help researchers gain insights into the complex interactions between microbes and their host organisms, paving the way for new discoveries in the fields of human health, agriculture, and environmental science.
As the costs of sequencing and analysis continue to decline, it is becoming increasingly feasible for researchers in low-income and emerging countries to study microbiomes and contribute to the field. This could lead to more widespread adoption of microbiome sequencing services and support the growth of the market in these regions. In addition, increasing awareness of the importance of microbiome analysis in healthcare and disease prevention is also likely to drive demand for microbiome sequencing services globally.
The market is primarily segmented based on technology, application, end use, and region.
By Technology |
By Application |
By End Use |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
Synthesis segment garnered the largest share and will also grow at the steady rate. Sequencing by synthesis (SBS) is a widely used method in microbiome sequencing and is expected to boost the revenue of the segment. SBS enables high-throughput sequencing of millions of DNA fragments in parallel, which makes it an efficient and cost-effective method for analyzing the microbiome. This has resulted in a lot of interest in studying bacterial populations in different organs and tissues, including the gut and skin, to better understand the role of the microbiome in health and disease.
Gastro-intestinal segment held the significant share. The gut microbiome plays a critical role in maintaining the health of the digestive system, and changes in the microbiome can lead to a range of gut-related diseases. The use of microbiome sequencing to study the gut microbiome has enabled researchers to identify key microbial species and their roles in the development and progression of gut-related diseases. As a result, there is a growing interest in using microbiome sequencing to develop personalized therapies for gut-related diseases. This has led to increased research and development activities in this field, which is expected to drive segmental revenue growth.
Autoimmune disorders segment registered the steady growth. The human microbiome has been linked to various autoimmune diseases, and microbiome sequencing services have the potential to identify microbial changes that could contribute to autoimmune disorders. As healthcare professionals become more aware of the potential applications of microbiome sequencing in disease diagnosis and treatment, demand for these services is likely to increase, contributing to segment growth. Additionally, the availability of advanced microbiome sequencing technologies and analysis tools will likely facilitate research in this area and drive market growth.
Research institutes held the significant share. Microbiome sequencing services are also used for the analysis of small molecules and proteins in addition to DNA sequencing. This is particularly useful for drug discovery and development as well as biomarker discovery. As a result, there is a growing demand for microbiome sequencing services for protein in research institutions, which is expected to contribute to the segment's growth.
Pharmaceutical companies segment registered the steady growth rate. The pharmaceutical and biopharmaceutical industries are increasingly investing in microbiome research, and the use of microbiome sequencing services is becoming more widespread in drug discovery and development. This is because the microbiome has been shown to play an important role in human health and disease, and the development of microbiome-based therapies is a rapidly growing field. As a result, there is a growing demand for microbiome sequencing services to help researchers identify and study the complex interactions between the microbiome and the human body, as well as to identify potential drug targets and biomarkers.
North America held the largest share. American Cancer Society (ACS). North America is expected to hold a significant share of the microbiome sequencing services market due to the high prevalence of chronic diseases, the increasing demand for personalized medicine, and the presence of major players in the region. Additionally, the growing awareness among healthcare professionals and patients regarding the potential benefits of microbiome sequencing services is also expected to contribute to market growth in North America. According to the ACS, in 2020 there were an estimated 1.8 million new cancer cases and 606,520 cancer deaths in the United States.
Asia Pacific is expected to be the fastest growing in the global market over the forecast period. The region is witnessing a surge in the demand for microbiome sequencing services, owing to several factors such as an increase in research funding, growing awareness about personalized medicine, and rising government initiatives for the development of advanced healthcare infrastructure.
Rising microbiome sequencing based services in the region is also supported by the increasing prevalence of chronic diseases, such as cancer and diabetes, which require advanced diagnostic and treatment options. Furthermore, the availability of skilled professionals and cost-effective solutions in countries like China & India is also contributing to the growth of the market in the region.
Some of the major players operating in the global market include Microbiome Insights, Baseclear, Clinical-Microbiomics, Mérieux NutriSciences Corp., MR DNA, Metabiomics Corp., Rancho BioSciences, Second Genome, Zymo Research Corporation, and uBiome.
Report Attributes |
Details |
Market size value in 2024 |
USD 329.5 million |
Revenue forecast in 2032 |
USD 1,032.39 million |
CAGR |
15.30% from 2024 - 2032 |
Base year |
2023 |
Historical data |
2019- 2022 |
Forecast period |
2024 - 2032 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2032 |
Segments covered |
By Technology, By Application, By End Use, By Region |
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
Key companies |
Microbiome Insights, Baseclear, Clinical-Microbiomics, Mérieux NutriSciences Corp., MR DNA, Metabiomics Corp., Rancho BioSciences, Second Genome, Zymo Research Corporation, and uBiome. |
The Microbiome Sequencing Services Market report covering key are technology, application, end use, and region.
Microbiome Sequencing Services Market Size Worth $1,032.39 Million By 2032.
The global microbiome sequencing services market expected to grow at a CAGR of 15.3% during the forecast period.
North American is Microbiome Sequencing Services Market.
key driving factors in Microbiome Sequencing Services Market are Technological advancements in next-generation sequencing.